课题基金 / 基金详情

Development of a CRISPR/Cas9 gene editing platform to correct Severe Combined Immunodeficiency caused by mutations in the IL7RA gene

Development of a CRISPR/Cas9 gene editing platform to correct Severe Combined Immunodeficiency caused by mutations in the IL7RA gene
开发 CRISPR/Cas9 基因编辑平台以纠正由 IL7RA 基因突变引起的严重联合免疫缺陷
批准号:
MR/W001314/1
负责人:
Alessia Cavazza
金额:
$44.55万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2021
资助国家:
英国
项目状态:
已结题
起止时间:
2021 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
严重联合免疫缺陷(SCID)是一种罕见的由大量基因突变引起的遗传病,以免疫系统发育紊乱为特征。IL7RA基因突变是第三种最常见的SCID类型。IL7RA SCID患者不会产生t细胞,通常在生命早期受到严重的细菌、病毒或真菌感染的影响。如果不及时治疗,这些婴儿通常会在一年内因严重感染而死亡,除非他们接受了成功的造血干细胞移植。最近,基因治疗不同形式的SCID已经成功地尝试作为骨髓移植的替代方案。在基因治疗过程中,造血干细胞在实验室进行校正,然后注入患者体内,在那里它们开始产生健康的免疫细胞。然而,在造血干细胞中引入IL7RA正确拷贝的基因治疗尝试表明,该基因的组成性和不受调节的表达易导致白血病。另一种方法是通过使用基因编辑,将正常的基因拷贝直接引入其内源性位点,从而维持其生理调节,从而纠正造血干细胞。我们的初步数据证明了这种应用于IL7RA SCID的可行性。我们确实开发了基因编辑试剂和方案,以有效地敲入人类造血干细胞中IL7RA位点的报告基因。我们现在的目标是向前推进并敲入IL7RA的正确拷贝,以恢复来自SCID患者的IL7RA缺陷造血干细胞中的IL7RA表达。我们还旨在证明,移植经过校正的干细胞允许所有血细胞的发育,特别是t细胞,并且这个过程只产生很小的毒性,甚至没有毒性。开发一种基于基因编辑的治疗方法来治疗IL7R蛋白缺乏症,将为患有这种疾病的儿童提供有价值的替代方案。由于我们在基因编辑和造血干细胞操作方面的专业知识,我们认为我们处于实现这一目标的最佳位置。
英文摘要
Severe combined immunodeficiency (SCID) is a rare genetic disorder caused by numerous genetic mutations and characterized by the disturbed development of the immune system. Mutations in the IL7RA gene cause the third most common form of SCID. IL7RA SCID patients do not develop T-cells and are usually affected by severe bacterial, viral, or fungal infections early in life. These babies, if untreated, usually die within one year due to severe infections unless they have undergone successful hematopoietic stem cell transplantation. More recently, gene therapy for different forms of SCID has been successfully attempted as an alternative to bone marrow transplant. For the gene therapy procedure, hematopoietic stem cells are corrected in a laboratory and then infused back to the patient where they start producing healthy immune cells. However, gene therapy attempts to introduce a correct copy of IL7RA in hematopoietic stem cells showed that constitutive and unregulated expression of the gene pre-disposes to leukemia. An alternative approach is to correct the hematopoietic stem cells by introducing a normal copy of the gene directly in its endogenous locus, thus maintaining its physiological regulation, through the use of gene editing. Our preliminary data demonstrates the feasibility of such application for IL7RA SCID. We have indeed developed gene editing reagents and protocols to efficiently knock-in a reporter gene into the IL7RA locus in human hematopoietic stem cells. We now aim to move forward and knock-in a correct copy of IL7RA, in order to restore IL7RA expression in IL7RA-deficient hematopoietic stem cells from SCID patients. We also aim to demonstrate that transplantation of corrected stem cells allows the development of all blood cells, and in particular of T-cells, and that the process causes minimal to no toxicity. The development of a gene editing-based therapeutic approach to treat IL7R protein deficiency will provide a valuable alternative for children with this disease. Thanks to our expertise in gene editing and manipulation of hematopoietic stem cells we feel we are in the best position to achieve this goal.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1089/hum.2023.100
发表时间: 2024-02-29
期刊: HUMAN GENE THERAPY
影响因子: 4.2
作者: [Rai,Rajeev, Steinberg,Zohar, Cavazza,Alessia]
通讯作者: Cavazza,Alessia
DOI: 10.3389/fimmu.2022.966084
发表时间: 2022
期刊: Frontiers in immunology
影响因子: 7.3
作者: []
通讯作者:
国内基金
海外基金
利用CRISPR/Cas9和单细胞多组学技术探索IRF-1介导代谢重编程在肝缺血再灌注损伤后肝脏再生中的作用机制
  • 批准号:
    2026JJ50622
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    罗静
  • 依托单位:
全基因组CRISPR/Cas9文库筛选发现IGF1R通过抑制细胞焦亡途径诱导结直肠癌奥沙利铂耐药的机制研究
  • 批准号:
    2026JJ80578
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    杨熙华
  • 依托单位:
CRISPR/Cas9精确编辑NOTCH2NLC基因GGC重复扩增突变的治疗策略探究
  • 批准号:
    2026JJ50082
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    谢妮娜
  • 依托单位:
基于CRISPR/Cas9基因编辑技术及雌核发育技术快速获得无肌间刺金背鲤新种质的研究
  • 批准号:
    2026JJ30134
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    李俊
  • 依托单位: